Wordt geladen...
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing–remitting multiple sclerosis (TIME MS)
Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple s...
Bewaard in:
Hoofdauteurs: | , , , , , , , , , , |
---|---|
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
SAGE Publications
2010
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3002615/ https://ncbi.nlm.nih.gov/pubmed/21180632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285609355851 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|